A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Primary Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility.

Trial Profile

A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Primary Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2013

At a glance

  • Drugs Semuloparin (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism; Venous thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms SAVE-VEMED
  • Sponsors Sanofi
  • Most Recent Events

    • 05 May 2010 Actual number of patients (421) added as reported by ClinicalTrials.gov record.
    • 25 Mar 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 05 Feb 2009 Planned end date changed from 1 Mar 2011 to 1 Mar 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top